Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Liabilities and Shareholders Equity data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $3.3 billion, changed N/A, while the annual FY2025 figure was $1.1 billion, N/A changed from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per RCUS's latest filing, up from $974.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q4 2021 and bottomed at $839.3 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 430.88% in 2021, then fell 25.08% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.6 billion in 2021, then decreased by 18.34% to $1.3 billion in 2022, then decreased by 15.77% to $1.1 billion in 2023, then increased by 18.72% to $1.3 billion in 2024, then dropped by 12.38% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.1 billion in Q4 2025, $974.0 million in Q3 2025, and $1.2 billion in Q1 2025.